新型冠状病毒抗原快速检测专家共识(2022)

Expert Consensus on Rapid SARS-CoV-2 Antigen Testing(2022)

  • 摘要: 新型冠状病毒肺炎疫情持续时间长、流行范围广,给全球公共卫生带来了巨大负担。作为感染早期诊断和疫情防控的主要检测手段之一,新型冠状病毒抗原快速检测已在国内逐步开展临床应用。就目前医务人员和社会公众所关注的新型冠状病毒抗原检测相关问题,中国医院协会临床微生物实验室专业委员会组织医学检验、临床医学、感染控制、公共卫生及体外诊断产品研发等多领域专家,依据国内外最新研究进展和应用实践,共同制定了《新型冠状病毒抗原快速检测专家共识(2022)》。本共识介绍了目前新型冠状病毒抗原快速检测方法的技术原理、性能特点、结果解读及处置建议,并就不同场景下新型冠状病毒抗原快速检测应用策略和注意事项进行了解析,以期为临床诊疗和疫情防控中正确理解和应用这一检测技术提供参考建议。

     

    Abstract: The epidemic of the highly contagious, long lasting and widely popular coronavirus disease 2019 (COVID-19) has imposed a huge burden to the global public health. As one of the key methods for early diagnosis of COVID-19 infection, rapid acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen testing has been gradually applied in China. To address concerns raised by both health care workers and the public, based on the latest research and clinical practices, the Sub-committee of Clinical Microbiology Laboratory, Chinese Hospital Association proposed Expert Consensus on Rapid SARS-CoV-2 Antigen Testing (2022). The consensus panel is composed of experts from multiple disciplines, including laboratory medicine, clinical medicine, infection control, public health, research and development of in vitro diagnostic products. The consensus describes its principle, technological characteristics, results interpretation and disposal recommendations, and analyzes the strategies and matters needing attention in different application scenarios. We expect the consensus to help correct understanding and application of rapid SARS-CoV-2 antigen testing in the diagnosis, treatment, prevention, and control of COVID-19.

     

/

返回文章
返回